Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry.

Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P608).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PRO Kidney
2018
Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018.

Oncol Res Treat 41 (suppl 4)(P912).

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NEPTUN
2018
First-line pazopanib in poor-risk patients with metastatic renal cell carcinoma.

Staehler, M., Panic, A., Merling, M., Vannier, C., Hermann, E., Hogrefe, C., Potthoff, K., Grünwald, V., 2018.

Oncol Res Treat 41 (suppl 4)(P606).

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
FLIPPER
2018
Palbociclib in combination with letrozole as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welslau, M., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P919).

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
INGE-B
2018
An observational study to evaluate the effectiveness of OnLife® in improving chemotherapy-induced peripheral neuropathy in patients with colon or breast cancer after end of adjuvant therapy: Design of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P945).

Indikation: Breast Cancer, Colorectal Cancer, Kolorektalkarzinom, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
STEFANO
2018
Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study.

Knauf, W., Ammon, A., Merling, M., Hurtz, H.-J., Vannier, C., Schulz, H., Marschner, N., Riedt, T., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P572).

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARO
2018
Does progression influence the quality of life? – Data from patients with advanced breast cancer from the MaLife-Project.

Marschner N., Söling, U., Scholz, H., Azeh, I., Chiabudini, M., Kruggel, L., Jänicke, M., 2018.

Oncol Res Treat 41 (suppl.4) (V493)

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2018
1st-line therapy of patients with Waldenström Macroglobulinemia: Treatment reality and outcome data from the German prospective TLN Registry.

Knauf, W., Slawik, H.R., Bückner, U., Houet, L., Wetzel, N., Jänicke, M., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P181), 47-48

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2018
MYRIAM: Prospective, intersectoral Real World cohort study for treatment and outcome of myeloma patients in Germany.

Knauf, W., Engelhardt, M., Lipke, J., Losem, C., Kasper, C., Dörfel, S., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

Oncol Res Treat 41 (suppl 4)(P574), 190.

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2018
Survival of Non-Transplant Patients with Multiple Myeloma in Routine Care Differs from That in Clinical Trials—data from the Prospective German Tumour Registry Lymphatic Neoplasms.

Knauf, W., A. Aldaoud, U. Hutzschenreuter, M. Klausmann, S. Dille, N. Wetzel, M. Jänicke, N. Marschner, and the TLN-Group (Tumour Registry Lymphatic Neoplasms).

Annals of Hematology, 1 August 2018, 1–9. https://doi.org/10.1007/s00277-018-3449-8.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Annals of Hematology
TLN
2018